PEGFILGRASTIM BIOSIMILARS MARKET Size and trends

Pegfilgrastim Biosimilars Market Size and Trends

Global pegfilgrastim biosimilars market is estimated to be valued at USD 1.84 Bn in 2025 and is expected to reach USD 3.39 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 9.1% from 2025 to 2032.

To learn more about this report, Request sample copy

The market  growth is driven by rising demand for cheaper biosimilar alternatives to the reference biologic drugs from patients struggling with healthcare costs. Biosimilars offer significant cost savings as compared to their reference biologics, and this boosts purchase of pegfilgrastim biosimilars by hospitals and cancer care centers. Rising incidence of cancer cases worldwide boosts the need for supportive care therapies such as pegfilgrastim. Moreover, the expiry of patents of major reference biologic drugs enable the commercialization of various novel biosimilars in the market. This can expand treatment access to more patients.

Increasing number of cancer cases

Rising incidence of cancer worldwide boosts  demand for supportive cancer care therapies. According to WHO, cancer burden has nearly doubled since 2000 and is expected to increase in the near future. Cancer chemotherapy often results in severely low white blood cell count in patients, making them vulnerable to life-threatening infections. Pegfilgrastim is administered to patients undergoing chemotherapy to boost white blood cell count and reduce chances of infections. As more cancer patients opt for chemotherapy globally each year, there will be huge demand for pegfilgrastim to protect them from neutropenia.